The University of California, Los Angeles (UCLA) has announced an agreement with Switzerland-based biotech company Roche. Under the deal, Roche will provide UCLA's stem cell and cancer researchers with the latest technologies that will drive research capabilities and further the understanding of complex disease.
The technologies include the latest generation microarray systems from Roche NimbleGen, high-throughput screening instruments, genetic expression profilers and exome sequencing technologies. These will reportedly provide scientists with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and UCLA's Jonsson Comprehensive Cancer Center with key technology directly from Roche's R&D pipeline.
Roche will also provide UCLA with advanced reagent, technologies and bioinformatics support to be used in the pursuit of discovering new predictive biomarkers. These will be used as targets for future therapeutics and diagnostics for a host of diseases.
The agreement is seen to open the door for UCLA and Roche scientists to work collaboratively with an initial focus on developing even more effective technologies for academic and commercial use. Future developments, based on these technologies, could lead to clinical trials of promising diagnostics and therapeutics.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
